Respiratory Collaboration and Licensing Deals 2016-2026

Key Benefits

✔ Benchmark against 464 respiratory partnering deals – Access a focused body of real-world collaboration and licensing activity to identify relevant precedents and comparable transactions.

✔ Benchmark respiratory deal financials – Analyze disclosed headline values, upfront payments, milestones and royalty rates and investigate the individual transactions behind the benchmarks.

✔ Identify prospective partners and leading dealmakers – Discover companies with demonstrated interest in respiratory assets, technologies, therapeutic indications, targets and relevant stages of development.

✔ Compare activity across the respiratory landscape – Analyze dealmaking by therapeutic indication and target, development stage, technology type, deal type, industry sector and company.

✔ Find the most relevant comparable transactions – Move beyond broad averages to identify deals involving similar indications, targets, technologies, development stages and partnering structures.

✔ Understand how respiratory deals are structured – Examine licensing rights, development responsibilities, exclusivity, IP, commercialization rights, milestones, royalties and other important transaction provisions.

✔ Learn from real contract documents – Where publicly available, review underlying agreements to understand how rights, obligations, financial terms and other negotiated provisions have been documented.

✔ Apply the intelligence to your own respiratory opportunity – Qualifying customers may also be eligible for a Customized Executive Partnering Briefing focused on their own asset, indication, target, technology, prospective partners or transaction objectives.

Executive Summary

 

Chapter 1 – Introduction

 

Chapter 2 – Trends in respiratory dealmaking

 

2.1. Introduction

2.2. Respiratory partnering over the years     

2.3. Respiratory partnering by deal type

2.4. Respiratory partnering by industry sector

2.5. Respiratory partnering by stage of development

2.6. Respiratory partnering by technology type

2.7. Respiratory partnering by therapeutic indication

 

Chapter 3 – Financial deal terms for respiratory partnering

 

3.1. Introduction

3.2. Disclosed financials terms for respiratory partnering

3.3. Respiratory partnering headline values

3.4. Respiratory deal upfront payments

3.5. Respiratory deal milestone payments

3.6. Respiratory royalty rates

 

Chapter 4 – Leading respiratory deals and dealmakers

 

4.1. Introduction

4.2. Most active in respiratory partnering

4.3. List of most active dealmakers in respiratory    

4.4. Top respiratory deals by value

 

Chapter 5 – Respiratory contract document directory

                                            

5.1. Introduction

5.2. Respiratory partnering deals where contract document available

 

Chapter 6 – Respiratory dealmaking by therapeutic target

 

6.1. Introduction

6.2. Deals by respiratory therapeutic target

 

Deal directory

 

Deal directory – Respiratory deals by company A-Z

Deal directory – Respiratory deals by technology type

 

Deal type definitions

 

About Biopharma Research Ltd

 

Current Partnering

Current Agreements

Recent report titles from Current Partnering

 

Table of figures

 

Figure 1: Respiratory partnering since 2016

Figure 2: Respiratory partnering by deal type since 2016

Figure 3: Respiratory partnering by industry sector since 2016

Figure 4: Respiratory partnering by stage of development since 2016

Figure 5: Respiratory partnering by technology type since 2016

Figure 6: Respiratory partnering by indication since 2016

Figure 7: Respiratory deals with a headline value

Figure 8: Respiratory deals with upfront payment values

Figure 9: Respiratory deals with milestone payment

Figure 10: Respiratory deals with royalty rates

Figure 11: Active respiratory dealmaking activity since 2016

Figure 12: Top respiratory deals by value since 2016

Pricing options

• $3,995: single-user (encrypted file - one user/device)
• $5,995: multi-user (encrypted file - up to 5 users/devices)
• $7,995: company (unencrypted file)

Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin3 PDF Reader will be provided at report delivery.

Company license files are not encrypted and can be accessed using a PDF Reader.

A full explanation of license type definitions can be found here.

 

Our guarantee

 

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

 

Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)

 

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

 

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by Evalon.

 

Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

3M, 4D Molecular Therapeutics, 4D Pharma, AazeinTx, Abbott Laboratories, Abbvie, Abingworth Life Sciences, Abionic, ABVC BioPharma, Acceleron Pharma, Aclaris Therapeutics, Acrobat Genomics, Actelion, AdAlta, Adalvo, Adamis Pharmaceuticals, adMare BioInnovations, ADM Tronics, Advanced Biological Laboratories, Advanz Pharma, Advent Therapeutics, Aerami Therapeutics, Aerogen, AeroRx Therapeutics, Aerpio Pharmaceuticals, AGC Biologics, AgeX Therapeutics, Aidoc, AirNexis Therapeutics, AIT Therapeutics, Akari Therapeutics, Akonni Biosystems, Albany Molecular Research, Alex Therapeutics, Allakos, Allegheny Technologies, Allinaire Therapeutic, Alpine Immune Sciences, Altavant Sciences, Altum Pharmaceuticals, Aluna, Alvotech, American Association for Laboratory Accreditation, American College of Chest Physicians, American Lung Association, Amneal Pharmaceuticals, AMO Pharma, Amyndas Pharmaceuticals, Analytics 4 Life, AnGes MG, Anthem, Anthem Bluecross, Apple, Aptar Pharma, Aptuit, Arch Biopartners, Arcturus Therapeutics, Arena Pharmaceuticals, Aridis Pharmaceuticals, Aristea Therapeutics, Ark Biosciences, Arrowhead Pharmaceuticals, ARS Pharmaceuticals, ArtiQ, ARUP Laboratories, Aslan Pharma, AssisTek, Asthma UK, AstraZeneca, Athersys, Atrapos Therapeutics, aTyr Pharma, Avicenna Technology, Avrobio, AzarGen Biotechnologies, Bausch Health Companies, Bayer, Baylor Health Care System, Beijing Tide Pharmaceutical, Ben-Gurion University, BenevolentAI, Be The Match BioTherapies, Beth Israel Deaconess Medical Center, BetterLife Pharma, Beyond Air, Bicycle Therapeutics, Bill and Melinda Gates Foundation, Bio-Me, Bio-Techne, BioAegis Therapeutics, Bioforum, BioKey, BioLink Life Sciences, Biolojic Design, BioLum Sciences, Biomedical Advanced Research and Development Authority, BioMed X Innovation Center, Biophytis, BiosanaPharma, Biosion, BioVersys, Blanver, Blu Biotech, Blue Cross Blue Shield Association, Blue Shield of California, BNC Korea, Boehringer Ingelheim, Bonne Santé Group, Boomer Esiason Foundation, Bora Pharmaceuticals, Boston Scientific, Boston University School of Medicine, Brainomix, Breath Therapeutics, Bridge Biotherapeutics, Brigham and Women's Hospital, BrightInsight, Bristol-Myers Squibb, British Lung Foundation, Broncus Technologies, Brown University, C4X Discovery, California Institute for Biomedical Research, California Institute for Regenerative Medicine, Cambridge Healthcare Innovations, Canadian Blood Services, Cannex Scientific, Cantex Pharmaceuticals, CARB-X, Cardiff University, Cardiovascular Systems, Carnegie Mellon University, Cedars-Sinai Medical Center, Celgene, Cellect Biotechnology, CELLINK, Cellix Bio, Celltrion, Celularity, Charak Foundation, Charite Universitatsmedizin Berlin, Chiesi Farmaceutici, Children's Hospital Boston, China Medical System, Chronolife, Cilag AG, Cincinnati Children’s Hospital Medical Center, Cipla, Circassia, Citius Pharmaceuticals, Clalit Health Services, Clario, CN Bio, Coalition for Epidemic Preparedness Innovations, Coeptis Therapeutics, CohBar, Collplant, Combioxin, Commense, Commonwealth of Pennsylvania, CompleWare, Context Therapeutics, COPD Foundation, Corsair Pharma, Cosmo Pharmaceuticals, CosmosID, Covalon Technologies, COVIRIX Medical, CRS Bio, CrystecPharma, CSL, CSL Behring, CS Pharmaceuticals, Cue Health, Curadev Pharma, Curetis, CureVac, CVD Equipment, CytoReason, Cytovation, Daewoong Pharmaceutical, Dalton Pharma Services, Department of Defense, Dermira, Deverra Therapeutics, DevPro Biopharma, Diffusion Pharmaceuticals, Diomics, Donnelley Financial Solutions, DSG, Duke Clinical Research Institute (DCRI), Duke University, Dymax, Eagle Pharmaceuticals, Edesa Biotech, Eisai, Eli Lilly, Empatica, Empirico, ENA Respiratory, Endpoint Health, Enzyvant Science, Epistemic AI, Erasmus University Medical Center, Essential Pharmaceuticals, Ethris, European Union, Everest Medicines, EvolveImmune Therapeutics, Evommune, Evotec, Experimental Therapeutics Centre of Singapore, Fannin, Faron Pharmaceuticals, FibroGenesis, Flagship Pioneering, Florica Therapeutics, Fluidda, fluidIQ, Food and Drug Administration (FDA), Foresee Pharmaceuticals, Forge Therapeutics, Foundation for Sarcoidosis Research, Fred Hutchinson Cancer Research Center, Fujifilm Diosynth Biotechnologies, FUJIFILM SonoSite, Fulcrum Therapeutics, Fusion Genomics, Galapagos, Gatehouse Bio, Geisinger Health System, GEn1E Lifesciences, Genentech, Genomadix, Genome Institute of Singapore, GenScript ProBio, Genten Therapeutics, German Government, Getz Healthcare, Gilead Sciences, Glenmark Pharmaceuticals, Glenmark Pharmaceuticals S.A., Global Access Diagnostics, Global Coalition for Adaptive Research, GlobalLogic, GoodRx, Gossamer Bio, Government of Canada, Government of Israel, GPCR Therapeutics, Graviton Bioscience, Green Park Collaborative, GRI Bio, Grifols, GSK, Guangzhou Institute of Respiratory Disease, Haisco Pharmaceutical, Hangzhou Chance Pharmaceuticals, Haplogen, Harbour Biomed, Harvard Stem Cell Institute, Harvard University, Harvest Capital Strategies, HCmed Innovations, Healios K.K., Healium Medical, Health Care Originals, HealthPrize Technologies, HealthSnap, HealthTrust Purchasing Group, Hebrew University of Jerusalem, Hemovent, Henry M. Jackson Foundation, Highmark Health, Hikma Pharmaceuticals, Honeywell, Hoth Therapeutics, Humanetics, Hyfe, i2c Pharmaceutical Services, iBio, IBM, Icagen, Iconovo, IDbyDNA, IDT Biologika, Illumina, Imbio, Immune Therapeutics, Imperial College London, Inari Medical, Incyte, Industrial Technology Research Institute, Inhalation Sciences, Inhalon Biopharma, Inhibrx, Innovare, Innovate UK, Innova Vascular, Innovus Pharmaceuticals, Inovalon, Inovio Pharmaceuticals, Inovytec, Insmed Inc, Inspira Technologies, Instem, Institut Kanser Negara, Integrated Computer Solutions, Intrexon, Inventiva, InVixa, Itamar Medical, Janssen Pharmaceuticals, Janssen Research & Development, Janssen Sciences, Jemincare, JHL Biotech, Jiangsu Hengrui Pharmaceuticals, Jiangsu QYuns Therapeutics, Jikei University, Johannes Gutenberg University, Johns Hopkins University, Johnson & Johnson Innovation, Kaleido Biosciences, Kamada, KangWon University Institute of Medical Science, KARE Biosciences, Karolinska Institute, Kashiv BioSciences, Kelun-Biotech Biopharmaceutical, Kennedy Institute of Rheumatology, Keyence, Kindeva Drug Delivery, Knopp Biosciences, Koye Pharmaceuticals, Kyorin Pharmaceutical, La Jolla Institute for Allergy & Immunology, Lassen Therapeutics, Launch Therapeutics, Laurel Venture Capital, Leading BioSciences, Lee's Pharmaceutical, Leidos, LEO Pharma, LianBio, LifeArc, Ligand Pharmaceuticals, Light Chain Bioscience, LightDeck Therapeutics, Lipigon Pharmaceuticals, Locus Biosciences, Lonza, Lotus Pharmaceuticals, Lumen Biomedical, Luminex, LuminUltra, Lundquist Institute, Lung Biotechnology, Lung Therapeutics, Lung Transplant Foundation, Lurie Children's Hospital of Chicago, Lyomark Pharma, Lyra Therapeutics, mAbXience, Mallinckrodt Pharmaceuticals, MannKind Biopharmaceuticals, Marinomed Biotechnologie, Marpai, Massachusetts General Hospital, Matrix Biomed, Max Biopharma, Mayo Clinic, Medela, Mediar Therapeutics, Medical International Research, Medical Technology Enterprise Consortium, Medicines Discovery Catapult, MediciNova, Medicom, MedImmune, MediPines, Meissa Vaccines, Meitheal Pharmaceuticals, Melinta Therapeutics, Melior Pharmaceuticals, Menarini, Menarini Asia-Pacific, Merck and Co, Mesoblast, Metaba, Methapharm, Microbio Shanghai, Moderna, Momenta Pharmaceuticals, Monopar Therapeutics, Morphic Therapeutic, Mount Sinai Health System, MS Pharma, Mundipharma, Mylan Pharmaceuticals, Myovant Sciences, Nanjing King-friend Biochemical Pharmaceutical, Nano-X Imaging, Nanopharm, NanoString Technologies, NantKwest, Nanyang Technological University, Nashville Biosciences, National Healthcare Services (NHS), National Health Service, National Heart, Lung and Blood Institute, National Institute for Environmental Health Sciences, National Institute for Health and Care Research Respiratory Translational Research Collaboration, National Institute of Allergy and Infectious Diseases, National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institutes of Health, National Jewish Health, National Kidney Foundation, National Organization for Rare Disorders, National Research Council Canada, National Science Foundation, Nepean Blue Mountains Local Health District’s Nepean Hospital, Nephron Pharmaceuticals, NeuCen BioMed, Neurocare Group, NeurOp, NeuroRx, Nexel, NitricGen, Nitto Denko, North Carolina State University, NorthStar Medical Radioisotopes, Northwestern University, Novartis, NoveCite, Novellus Therapeutics, NRx Pharmaceuticals, NTC, Nuance Pharma, Numedicus, NuMedii, NuvoAir, ObvioHealth, Olympus Respiratory America, Omdana Therapeutics, One BioMed, Oneness Biotech, Onymos, OpGen, Organicell Regenerative Medicine, Orgenesis, Orion, Oslo University Hospital, Owkin, Owlstone Medical, Palisade Bio, Pall Corporation, Pantherics, Paragonix Technologies, Paratek Pharmaceuticals, PARI Pharma, Partner Therapeutics, Patara Pharma, Patient-Centered Outcomes Research Institute, Peking University, Penumbra, Perrigo, Pharmbio Korea, PhaseBio Pharmaceuticals, Philips, Pieris Pharmaceuticals, Pluristem Therapeutics, Polarean Imaging, Polyphor, Precisio Biotix Therapeutics, Precision Image Analysis, Premier Inc, Primevera Therapeutics, Propeller Health, ProQR Therapeutics, Protalix BioTherapeutics, Provista Diagnostics, Pulmatrix, Pulmodyne, Pulmonary Fibrosis Foundation (PFF), Pulmonomy, PulmoSIM Therapeutics, Pulmotree Medical, Pulthera, Punjab Province, PureTech Health, QOL Devices, Quartesian Clinical Research, Quebec Government, Quercis Pharma, R4D Biotech, Rabin Medical Center (Beilinson Hospital), RapidAI, RAPT Therapeutics, ReAlta Life Sciences, Recipharm, Recludix Pharma, Recurrent Respiratory Papillomatosis Foundation, RedHill Biopharma, Redox, Redx Pharma, Relation Therapeutics, Renovion, Resilient Biotics, RespirAI Medical, Respira Therapeutics, RespiraWorks, RespireRx Pharmaceuticals, resTORbio, Revon Systems, RION, Roche, Roivant Sciences, Royal Philips Electronics, RS BioTherapeutics, Rubedo Life Sciences, RxCap, Samumed, Sandoz, Sanofi, Santhera Pharmaceuticals, SarcoMed USA, Sarepta Therapeutics, Savana, Savara Pharma, Scholar Rock, Science 37, Scleroderma Research Foundation, Seelos Therapeutics, Sema4, Sensible Medical Innovations, SenzaGen, Seqirus, Seqster, Serum Institute of India, Seyltx, Shandong Luoxin Pharma, Shanghai Ark Biopharmaceutical, Shaperon, Sheba Medical Center, Shenzhen Institutes of Advanced Technology, Siemens Healthineers, Silence Therapeutics, Simulations Plus, Siolta Therapeutics, SiteOne Therapeutics, Sleepiz, Sonde Health, Sonmol, Sosei Heptares, SpeeDx, Spesana, Spire Health, SQI Diagnostics, Stanford University School of Medicine, Statera Biopharma, Stemedica Cell Technologies, Stevanato, Stimit, Strados Labs, Sumitomo Dainippon Pharma, Sumitovant Biopharma, Sunnybrook Research Institute, Sunovion Pharmaceuticals, SUNY Upstate Medical University, Surrozen, Sutter Health, Suzhou Intragrand Pharma, Synergie Lyon Cancer, Synthonics, Taiba, Taiho, Takeda Pharmaceutical, TARGET PharmaSolutions, TB Alliance, TCGFB, Tektronix Component Solutions, Teleflex, Telesair, TeraRecon, Tetra Bio-Pharma, Teva Pharmaceutical Industries, Texas Lung Injury Institute, TFF Pharmaceuticals, TFS International, The Alfred Hospital, Therma Bright, Thermo Fisher Scientific, Third Pole Therapeutics, Three Lakes Foundation, TiGenix, Tivic Health Systems, TMM Software, toSense, Translate Bio, Transpire, Transpire Bio, Trevena, TrialSpark, TSI Healthcare, United Therapeutics, University of California, Davis, University of California, San Diego, University of California San Francisco, University of Chicago, University of Colorado, University of Dundee, University of Florida, University of Georgia, University of Glasgow, University of Houston, University of Manchester, University of Maryland Baltimore, University of Melbourne, University of Michigan, University of Montana, University of Munster, University of Oklahoma, University of Oxford, University of Pennsylvania, University of Pittsburgh, University of Pittsburgh Medical Center, University of Sheffield, University of Surrey, University of Texas at El Paso, University of Texas Health Science Center at Tyler, University of Virginia, University of Wisconsin, Urovant Sciences, US Army, US Army Medical Research and Material Command, US Army Medical Research Institute of Chemical Defense, Utrecht University, UWM Research Foundation, Vanderbilt University, Vapotherm, Variant Bio, Vasomune Therapeutics, Vectura, Veeva Systems, VenatoRx, Veracyte, Verantos, Verily, Verona Pharma, Vicore Pharma, Vida Diagnostics, Virginia Catalyst, Visby Medical, Vituity, Viz.ai, Vocalis Health, Vortran Medical, Watchmaker Genomics, WaVe Lifesciences, Weill Cornell Medical College, Windtree Therapeutics, Windward Bio, Wuxi STA, Wyss Institute, Xerox, XL-Protein, Xvivo Perfusion, Xylyx Bio, Yale School of Medicine, Yale University, Yissum Research Development, YPrime, ZappRx, Zentiva, ZEPHYRx, Zymedi

About Current Partnering

A definitive, evidence-based approach to dealmaking intelligence

Current Partnering is the industry-leading provider of pharmaceutical and biotech dealmaking intelligence, delivering a clear, structured, and evidence-based view of how partnerships are designed, negotiated, and executed in practice.

Our reports combine comprehensive deal coverage, structured data analysis, and contract-level insight, enabling a deeper understanding of how financial terms, rights, and responsibilities are defined across real-world transactions.

All reports are updated every six months, ensuring users have access to the latest deal activity, trends, and market developments.

---

Our methodology

Built on a continuously updated proprietary database

All analysis is underpinned by Current Agreements, our proprietary deals and alliances database which is updated daily by our analysts as new transactions are announced globally.

Deal records are continuously reviewed and enriched as additional information becomes available, ensuring accuracy, completeness, and relevance.

---

Comprehensive and verifiable data sourcing

Deal data is sourced from publicly available industry disclosures, including:

• Company press releases and announcements
• SEC filings and equivalent regulatory disclosures
• Company and investor presentations
• Conference materials and company websites

All sources are captured and referenced, enabling full transparency and user verification.

---

Broad coverage across deal types and structures

Current Partnering provides comprehensive coverage across a wide range of deal types, including but not limited to:

• Licensing and co-development
• Research and collaborative R&D
• Manufacturing, supply, and distribution
• Commercialisation and co-promotion
• Equity investments, joint ventures, and asset transactions
• Options, royalties, and financing agreements

This breadth ensures a complete view of how partnerships are structured across the life sciences sector.

---

Structured, standardised analysis

Every deal is analysed using a consistent framework, capturing (where disclosed):

• Financial terms — including upfront payments, milestones, and royalties
• Rights allocation — development, manufacturing, and commercialization responsibilities
• Deal structure — exclusivity, territorial scope, and agreement type
• Contractual provisions — clauses defining risk, control, and value-sharing

Each deal record is fully categorised, including data fields such as:

• Therapy area and technology type
• Stage of development
• Asset type and deal components
• Geographic scope and exclusivity
• Source documentation, including press releases and SEC filings

---

Financial normalisation for comparability

All financial values are standardised to USD using the exchange rate at the time of deal announcement, enabling consistent comparison of deal terms across geographies.

---

Contract-level insight

Where available, reports include direct access to underlying agreement documents, providing visibility into how deals are constructed in practice.

This enables users to understand:

• How financial mechanisms are defined and triggered
• How responsibilities are operationalised between parties
• How flexibility, risk, and control are allocated within agreements

---

Designed for real-world application

Current Partnering reports are built to support business-critical decision-making across the life sciences ecosystem, including:

• Pharmaceutical and biotech companies — benchmarking deals, structuring transactions, and supporting licensing strategy
• Investment firms and venture capital — assessing deal benchmarks, valuation expectations, and partner behaviour
• Advisory, legal, and consulting firms — supporting client engagements with real-world precedent and contract-level insight

Common use cases include:

• Benchmarking comparable transactions
• Supporting valuation and deal structuring
• Preparing for negotiations
• Evaluating potential partners
• Informing internal strategy with real-world evidence

---

A trusted industry reference

With a long track record in the sector, Current Partnering is relied upon by leading pharmaceutical companies, emerging biotechs, investors, and advisory firms as a trusted source of dealmaking intelligence.

By combining proprietary data, rigorous methodology, and contract-level insight, our reports provide a reliable and authoritative foundation for understanding how deals are structured, negotiated, and valued.